

MPS FLASH TALKS 2021
October 16, 2021

MPS Fall Program, "Novel Approaches to Psychiatry"
Minnesota Humanities Center, St Paul, MN - Saturday, October 16, 2021



1

MANUEL GARDEA-RESENDEZ, M.D.
MAYO CLINIC

Lumateperone (Caplyta®)

MPS Fall Program, "Novel Approaches to Psychiatry"
Saturday, October 16, 2021



2

1. Brief Description/Background

- Unique mechanism of action due to tripartite modulation
 - 5-HT2A antagonist and 5-HT1A inhibitor
 - **Pre-synaptic D2 partial agonist** & postsynaptic D2 antagonist
 - **Indirect D1 receptor-dependent modulation of glutamate** (NMDA & AMPA)
- At low doses: ↑ sleep, ↓ agitation and aggression.
- At higher doses: antipsychotic and antidepressant efficacy

Correll et al., JAMA Psychiatry, 2020

MPS Fall Program, "Novel Approaches to Psychiatry"
Saturday, October 16, 2021



3

1. Brief Description/Background

- 4-week, randomized, double-blind, placebo-controlled (n=148) lamotepirone 42 mg (n=150) and 28 mg (n=150)
 - baseline to endpoint change in PANSS
 - 42 mg, not 28 mg, significant PANSS decrease
 - **No** difference in weight, metabolics, EPS, cardiac.
- Two placebo-controlled studies for bipolar depression:
 - lamotepirone 42 mg demonstrated favorable tolerability and safety profile
 - improved depressive symptoms
 - Most common adverse events: somnolence, dizziness and nausea
 - Rates of akathisia and EPS were similar to placebo

AB Sayeed @ JG Brasic, 2021
Psychiatric Times February 24, 2021 The First of Its Kind: A New Bipolar Depression Treatment



MP8 Fall Program, "Novel Approaches to Psychiatry"
Saturday, October 16, 2021

4

2. Indication(s)

- Intra-Cellular Therapies - Atypical antipsychotic FDA-approved (2019) for **schizophrenia**
- Submitted in 2021 for FDA approval for the treatment of **depressive episodes associated with bipolar I or II** disorder both as monotherapy and as adjunctive therapy in adults
- Rapidly absorbed, once-daily 42mg administered orally with food
- ↓ low risk for EPS and cardiometabolic side effects

AB Sayeed @ JG Brasic, 2021
Psychiatric Times February 24, 2021 The First of Its Kind: A New Bipolar Depression Treatment



MP8 Fall Program, "Novel Approaches to Psychiatry"
Saturday, October 16, 2021

5

3. Considerations

- Black box: ↑ risk of death for elderly patients with dementia-related psychosis
- Adverse effects: headache, somnolence, dizziness, sedation, fatigue, and constipation
- Caution when administered with inducers/inhibitors of CYP3A4
- ↑ cost (~\$1600/month)

AB Sayeed @ JG Brasic, 2021



MP8 Fall Program, "Novel Approaches to Psychiatry"
Saturday, October 16, 2021

6
